Bacterial therapy tolerable, shows early promise in patients with advanced solid tumors

A phase I clinical trial investigating the use of bacterial Clostridium novyi-NT spores as an injectable monotherapy had manageable toxicities and showed early clinical efficacy in patients with treatment-refractory solid tumor malignancies, according to data presented at the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, held Sept. 30-Oct. 3.
Read more: https://www.eurekalert.org/pub_releases/2018-09/aafc-btt092718.php?source=Snapzu